Erlotinib Hydrochloride
Reversible inhibition of the epidermal growth factor receptor tyrosine kinase is the pharmacology of erlotinib hydrochloride, which prevents receptor autophosphorylation and thereby interrupts downstream proliferative signalling. Tumours carrying activating EGFR mutations depend on that pathway, and it is in such tumours that the agent slows growth. The hydrochloride salt is the form presented in standard oral capsules, chosen for pharmaceutical rather than pharmacological reasons. Reversibility of binding distinguishes this generation of EGFR inhibitors from the covalent agents developed subsequently. The salt has the formula C22H24ClN3O4 and a molecular weight of approximately 429.9 g/mol, and it is approved with development completed through the final phase.
The hydrochloride salt form of erlotinib, this targeted cancer drug blocks the EGFR signaling pathway to slow the growth of EGFR-mutated tumors. The hydrochloride salt formulation is used in standard oral capsules.
Masse moléculaire
429,9000 g/mol
TPSA
74,70 Ų
Aires thérapeutiques
Mécanisme d'action
Reversible inhibitor of EGFR (HER1) tyrosine kinase, blocking autophosphorylation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Reversible inhibitor of EGFR (HER1) tyrosine kinase, blocking autophosphorylation.
Structure 2D
Cite this structure
Embed this structure
SMILES
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl
InChI
InChI=1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H
Molecular Formula
C22H24ClN3O4
HBD / HBA
2 / 7
Liaisons Rotatives
11
Atomes Lourds
30
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
The hydrochloride salt form of erlotinib, this targeted cancer drug blocks the EGFR signaling pathway to slow the growth of EGFR-mutated tumors. The hydrochloride salt formulation is used in standard oral capsules.
Reversible inhibitor of EGFR (HER1) tyrosine kinase, blocking autophosphorylation.
Yes, Erlotinib Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1079742. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 176871. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="erlotinib-hydrochloride"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/erlotinib-hydrochloride/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/erlotinib-hydrochloride/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/erlotinib-hydrochloride/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="erlotinib-hydrochloride"></drugfyi-drug>